To Our Global Community,
In a world of opportunity and innovation, Johnson & Johnson is committed to improving the health of people everywhere.
We are guided by Our Credo, a set of values that inspires our more than 153,000 employees to put the needs and well-being of the people we serve first. For 80 years, it has motivated us to solve complex health challenges with a spirit of innovation.
Improving the health for humanity is Our Purpose and shared responsibility. I am honored as Chairman and CEO to continue this legacy.
Our solid financial performance in 2022 was driven by an industry-leading portfolio of scientific and technological innovations that are reshaping many aspects of healthcare. Our Environmental, Social and Governance (ESG) strategy underpins our business performance with our Health for Humanity 2025 Goals as key performance indicators of our progress. These frameworks guide our decisions and direct our positive contributions to society, the economy and sustainable development. They also remind us how much more we can do for the world.
During a year of achievement and evolution, Johnson & Johnson met important global targets, including:
Championing global health equity
I am pleased that we ranked #2 on the 2022 Access to Medicine Index, which evaluates the world’s largest pharmaceutical companies on their efforts to distribute medicines to low- and middle-income countries. We also exceeded our Health for Humanity 2025 Goal to support 1.3 million frontline health workers with tools and training. Other initiatives include the Johnson & Johnson Center for Health Worker Innovation, which has committed $15 million over three years to the Africa Frontline First Catalytic Fund to expand the professional workforce of community health workers in ten African countries.
Empowering our employees
Our continued focus on accelerating diversity, equity, and inclusion outcomes helps us meet the changing needs of the communities we serve. I am proud that we achieved our Health for Humanity 2025 Goal of reaching 35 percent racial and ethnic diversity in U.S. management roles. We are also on track to achieve gender parity for women in management positions around the world. To upskill our employees, we launched J&J Learn, a dynamic development ecosystem to ensure easy access to learning and growth opportunities. We also enhanced mental health resources for our employees and their families.
Advancing environmental health
In 2022, we secured a deal to source 100 percent renewable electricity for our operations in Brazil. We also joined a collaboration of pharmaceutical companies to support ingredient suppliers’ efforts to decarbonize. In addition, we expanded our pharmaceuticals U.S. Safe Returns program to Switzerland, with plans to add more countries this year. Also in Europe, we expanded our single-use device hospital recycling program to eight countries and across three MedTech categories.
Leading with accountability and innovation
Grounded in the belief that science and technology will advance healthcare more in this decade than in the last century, we invested nearly $15 billion in R&D in 2022 and integrated digital capabilities into how we work.
Already, the use of data science in drug discovery has advanced our three treatments for multiple myeloma, the second most common blood cancer, providing transformational care for cancer patients.
Data science is also applied to our R&D ecosystem of medical devices, software, and robotics solutions, helping healthcare providers care for patients with greater precision and efficiency. Following the acquisition of Abiomed, Inc., the world leader in heart recovery solutions, we are integrating their technology and expanding our leadership in cardiovascular care.
Technology is also helping our supply chain make leaps forward in productivity, efficiency and sustainability. This fact was recognized by the World Economic Forum, which has granted 11 (three new in 2022) Lighthouse designations to our manufacturing facilities.
As we reflect on 2022’s accomplishments, we do so with an eye to a different but no less exciting future. In 2023, we are on track to advance two global companies: Kenvue—a new consumer health company—and Johnson & Johnson—dedicated to Pharmaceutical and MedTech—that will be uniquely positioned in a fast-moving healthcare landscape.
In this report, you will discover many other insights about how Johnson & Johnson is creating long-term and sustainable value.
In the years to come, we are committed to lead and seize opportunities for humanity while following Our Credo values.
Thank you for your interest.
Chairman of the Board and Chief Executive Officer
